Pharmaceuticals company AstraZeneca Pharma India announced FY24 results:
- Revenue from Operations for FY24 stood at Rs 1,296 crore with substantial 29% increase.
- Profit Before Tax is Rs 220 crore registering a commendable 64% growth (PBT before exceptional items at Rs 201 crore, up by 17% compared to previous financial year).
- Earnings Per Share (EPS) for financial year stood at Rs 64.6 demonstrating a significant growth of 63%
- The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for FY24, subject to approval of shareholders at the Annual General Meeting of the Company.
Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first time cross Rs 1000 crore mark, delivering total revenue of almost Rs ~1300 crore with growth of 29% this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areasin India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India.
Our scientific progress and great support from different states, peers, and industry stakeholders positions us optimally to achieve our purpose of leaving no patients behind in the therapy areas we are present in and sustainably continue our strive to contribute to people, society, and the planet."
Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflection of company’s focus on being a specialist organization & strong operational execution. This achievement reflects our relentless pursuit of identifying and capitalizing on opportunities in a dynamic environment. It underscores our dedication to not only achieving financial excellence but doing so in a sustainable and strategic manner."